Neoadjuvant Therapy clinical trials

Explore recruiting neoadjuvant therapy clinical trials.

Recruiting neoadjuvant therapy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neoadjuvant Therapy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatment with Inavolisib Combinations in Patients with Untreated, Early-Stage, PIK3CA-Mutated Breast Cancer

Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Neoadjuvant Chemotherapy for Obstructive Colon cancER first Treated by cOlostomy : A randomized phase III trial - COnCERTO (French 01-18) 2019/0407/HP

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

A randomized phase 2 trial of neoadjuvant pembrolizumab plus belzutifan with or without lenvatinib in patients with localized renal cell carcinoma. The moonlanding trial

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II multicentric study: efficacy evaluation of neo-adjuvant treatment associated with maintenance therapy by anti-PD1 immunotherapy on disease-free-survival (DFS) in patients with resectable mucosal melanoma (IMMUQ)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) or Hormone Receptor-low positive/HER2-negative Breast Cancer

France, Sweden, Poland, Spain, Finland, Portugal +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Neoadjuvant Therapy trials by city

Neoadjuvant Therapy in Toronto Neoadjuvant Therapy in Vancouver Neoadjuvant Therapy in Montreal Neoadjuvant Therapy in Calgary Neoadjuvant Therapy in Edmonton Neoadjuvant Therapy in Ottawa Neoadjuvant Therapy in Winnipeg Neoadjuvant Therapy in Quebec City Neoadjuvant Therapy in Hamilton Neoadjuvant Therapy in Kitchener Neoadjuvant Therapy in London Neoadjuvant Therapy in Halifax Neoadjuvant Therapy in New York Neoadjuvant Therapy in Los Angeles Neoadjuvant Therapy in Chicago Neoadjuvant Therapy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease